AMT-676

Phase 2Small molecule

MMultitude Therapeutics Inc.

AMT-676 is one of 82 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsRecruiting

Colorectal CancerRecruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Colorectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

25 2

Mfolfox6

Roche

Phase 3

5 3

Botensilimab

AAgenus Inc.

Phase 3

10 4

Zanzalintinib

Merck & Co.

Phase 3

1 5

5-Fu

TToray Industries, Inc

Phase 3

3 6

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 7

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 8

Clostridium Butyricum

XXijing Hospital of Digestive Diseases

Phase 3

1 9

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

1 10

Trodelvy

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Colorectal Cancer

NCT07474727

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

AMT-676 in Patients With Advanced Solid Tumors

Recruiting·MMultitude Therapeutics Inc.·Phase 1·NCT06400485·24 enrolled

Colorectal Cancer1 trial

An Phase II Study Evaluating the Safety and Efficacy of AMT-676 in Combination With 5-fluorouracil, Leucovorin, Bevacizumab (or Cetuximab) in Participants of Advanced Colorectal Cancer

Recruiting·MMultitude Therapeutics Inc.·Phase 2·NCT07474727·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AMT-676. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMT-676 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMT-676. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Multitude Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMultitude Therapeutics Inc.

AMT-676

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News